Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis

Elizabeth Kudlaty; Gayatri B. Patel; Michelle L. Prickett; Chen Yeh; Anju T. Peters

doi:10.1016/j.anai.2020.11.014

Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis

Elizabeth Kudlaty, Gayatri B. Patel, Michelle L. Prickett, Chen Yeh, Anju T. Peters

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	302-304
Number of pages	3
Journal	Annals of Allergy, Asthma and Immunology
Volume	126
Issue number	3
DOIs	https://doi.org/10.1016/j.anai.2020.11.014
State	Published - Mar 2021

Funding

Disclosures: Dr Peters is a consultant for Sanofi-Regeneron, AstraZeneca, and Optinose and receives research support from AstraZeneca and Optinose. The remaining authors have no conflicts of interest to report.Funding: This study receives funding from the Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine; Chronic Rhinosinusitis Integrative Studies Program (National Institutes of Health P01AI145818); National Institutes of Health T32AI083216; and Ernest Bazley Foundation.

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.anai.2020.11.014

Cite this

@article{ac430979ab10404d86f03ca1c4c4bdbe,

title = "Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis",

author = "Elizabeth Kudlaty and Patel, {Gayatri B.} and Prickett, {Michelle L.} and Chen Yeh and Peters, {Anju T.}",

note = "Funding Information: Disclosures: Dr Peters is a consultant for Sanofi-Regeneron, AstraZeneca, and Optinose and receives research support from AstraZeneca and Optinose. The remaining authors have no conflicts of interest to report.Funding: This study receives funding from the Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine; Chronic Rhinosinusitis Integrative Studies Program (National Institutes of Health P01AI145818); National Institutes of Health T32AI083216; and Ernest Bazley Foundation.",

year = "2021",

month = mar,

doi = "10.1016/j.anai.2020.11.014",

language = "English (US)",

volume = "126",

pages = "302--304",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "3",

}

TY - JOUR

T1 - Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis

AU - Kudlaty, Elizabeth

AU - Patel, Gayatri B.

AU - Prickett, Michelle L.

AU - Yeh, Chen

AU - Peters, Anju T.

N1 - Funding Information: Disclosures: Dr Peters is a consultant for Sanofi-Regeneron, AstraZeneca, and Optinose and receives research support from AstraZeneca and Optinose. The remaining authors have no conflicts of interest to report.Funding: This study receives funding from the Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine; Chronic Rhinosinusitis Integrative Studies Program (National Institutes of Health P01AI145818); National Institutes of Health T32AI083216; and Ernest Bazley Foundation.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85099646151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099646151&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2020.11.014

DO - 10.1016/j.anai.2020.11.014

M3 - Article

C2 - 33271296

AN - SCOPUS:85099646151

SN - 1081-1206

VL - 126

SP - 302

EP - 304

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 3

ER -

Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this